The Clorox Company (CLX) Up 6.5% — Time to Pull the Trigger?
The Clorox Company (CLX) delivered a sharp rebound on Tuesday, climbing 6.52% and adding $6.41 to close at $104.67 on the NYSE. The move came on the heels of Q4 FY2026 results that gave investors a cleaner read on where the business is heading once the noise from prior-year disruptions clears. Even with today's gain, CLX still sits roughly 18.8% below its 52-week high of $128.90, reached on February 26, 2026—leaving meaningful room for recovery if the forward momentum holds.
Volume told a notably emphatic story. Approximately 5.2 million shares changed hands, nearly double the 90-day average of around 2.7 million. That kind of surge in participation on a strong up day signals genuine conviction behind the move, not a low-volume drift higher.
Why The Clorox Company Price is Moving Higher
The clearest catalyst behind Tuesday's rally was Clorox's Q4 FY2026 earnings report, released on August 3, which delivered a meaningful beat on revenue and set a sales outlook that exceeded analyst expectations. Revenue came in at $1.948 billion against an anticipated $1.90 billion—a $48 million beat—while adjusted EPS of $1.66 edged past the $1.65 consensus. On the surface, the headline comparisons looked ugly: revenue fell 2% year over year and adjusted EPS dropped 42% from $2.87. But management provided the critical context that reframed both misses. The prior year's ERP-related inventory shipments artificially inflated last year's comparable period, reducing the latest quarter's organic growth by approximately 13.5 percentage points and dragging EPS down by roughly $0.90. Strip out that distortion, and the underlying operating picture looks far less alarming than the raw numbers suggest.
The FY2027 guidance was the real bullish catalyst that moved the stock. Clorox guided for net sales growth of 13% to 14%, above the 12.8% analyst estimate, with organic sales growth of 3.5% to 4.5% as the company finally laps the ERP disruption that has clouded comparisons for several quarters. Adjusted EPS guidance of $5.70 to $6.00 came in slightly below the $5.97 consensus, but the range still implies 3% to 8% growth from FY2026's $5.53—enough to reassure investors that earnings are inflecting upward rather than continuing to erode. The $2.25 billion GOJO acquisition contributed approximately 10 percentage points to reported sales growth, though integration and inventory step-up costs trimmed quarterly EPS by $0.32, a drag that investors expect to diminish as the deal matures.
Analyst reaction reinforced the constructive tone. Wells Fargo raised its price target on CLX from $95 to $102 following the report, and Jefferies moved its target from $98 to $100—both actions signaling that the Street is growing more comfortable with the view that the worst of the sales reset is behind the company. Gross margin contracted 520 basis points to 41.3%, and that pressure remains a live concern, but the upgraded revenue outlook gave analysts enough to work with to revise targets higher. For a stock sitting nearly 19% below its 52-week high, that combination of a credible sales acceleration story and institutional target increases was more than enough to trigger a significant repricing.
What is the The Clorox Company Rating - Should I Buy?
Weiss Ratings assigns CLX a C- rating. Current recommendation is Hold.
The sub-index picture is genuinely mixed, and that tension is exactly what a C- reflects. On the positive side, ROE of 546.10% earns the Excellent Efficiency Index—a figure that stands out even in the Consumer Staples sector, where mature brands typically generate steady but unspectacular returns on equity. In Clorox's case, the extreme ROE is largely a function of a heavily leveraged balance sheet that compresses the equity denominator, so it speaks more to capital structure choices than to pure operational excellence. Profit margin of 11.18% is respectable for a household products operator competing against large-scale peers with significant private-label exposure, and revenue growth of 0.12% earns a Good Growth Index—modest by any measure, but enough to register as directionally stable ahead of a year in which management has guided for a genuine acceleration.
The weak side of the ledger is harder to dismiss. The Weak Solvency Index reflects a balance sheet carrying meaningful debt, amplified by the GOJO acquisition financing. That leverage is a structural risk in a rate-sensitive environment, and it limits financial flexibility when macro conditions tighten. The Weak Total Return Index and Weak Volatility Index reinforce that CLX has not rewarded shareholders on a total return basis with the consistency investors expect from a defensive consumer brand, and the stock's price swings—including the sharp decline from the February 2026 high—have been wider than the sector's steadier names. The forward P/E of 15.94 is not particularly demanding, which limits downside on valuation alone, but it also means the stock is not obviously mispriced relative to its fundamental profile.
Within the Consumer Staples sector, Clorox ranks a step below The Procter & Gamble Company (PG, C), Kenvue Inc. (KVUE, C), and Kimberly-Clark Corporation (KMB, C), and two steps behind Colgate-Palmolive Company (CL, C+) and Church & Dwight Co., Inc. (CHD, C+). That relative ranking is consistent with the balance sheet concerns and muted growth history that have weighed on the stock—and it suggests that today's rally, while welcome, has not yet changed the fundamental calculus enough to shift the rating into buy territory.
About The Clorox Company
The Clorox Company (CLX ) is a Consumer Staples company with a portfolio of brands that occupy durable positions across cleaning, disinfecting, and personal care categories. The company's flagship bleach and disinfecting lines—marketed under the Clorox name—hold category-leading share in the U.S. retail channel, supported by decades of brand equity and consumer familiarity that generic and private-label alternatives have struggled to erode. Beyond its namesake products, Clorox owns a diversified set of well-known brands including Glad trash bags, Kingsford charcoal, Hidden Valley salad dressings, Burt's Bees natural personal care products, and Fresh Step cat litter, giving it broad exposure across multiple household spending categories.
The company's most significant recent strategic move was the $2.25 billion acquisition of GOJO Industries, the maker of Purell hand sanitizer and surface disinfectants. The deal meaningfully expands Clorox's professional and healthcare channel presence, adding a complementary business-to-business revenue stream alongside its predominantly retail-oriented legacy portfolio. Integration is ongoing, and while acquisition-related costs have weighed on near-term margins, the long-term rationale centers on cross-selling opportunities, shared distribution infrastructure, and the durability of the Purell brand in institutional settings where hygiene standards are non-negotiable.
Clorox's competitive position rests on strong retail shelf placement, a well-established supply chain, and significant investment in brand marketing that sustains pricing power in categories where consumers exhibit high brand loyalty. The company distributes globally, with the United States representing the majority of sales, and it continues to invest in reformulation and sustainability initiatives designed to strengthen its brand proposition in environmentally conscious consumer segments. These attributes give Clorox a degree of defensive resilience characteristic of leading Consumer Staples operators, even as it navigates an evolving cost and competitive landscape.
Investor Outlook
The Clorox Company (CLX) carries a Weiss Rating of C- (Hold), and Tuesday's rally reflects the market's improved confidence that the ERP-driven earnings distortions are finally clearing the rearview mirror. Investors should watch whether FY2027 organic growth of 3.5% to 4.5% materializes as guided and whether the GOJO integration begins contributing to margin recovery rather than continued compression—two developments that would be necessary to shift the fundamental case meaningfully. See full rankings of all C--rated Consumer Staples stocks inside the Weiss Stock Screener.
--